Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Laura Michaelis MD

Laura Michaelis MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


  • Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. (Michaelis LC, Klepin HD, Walter RB) Expert Opin Pharmacother 2018 Jun;19(8):865-882 PMID: 29697000 04/27/2018       1 Citations
  • Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 03/30/2018    
  • Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). (Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR) Leuk Res 2018 Apr;67:17-20 PMID: 29407182 02/07/2018    
  • Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. (Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP) Am J Hematol 2018 02;93(2):E49-E52 PMID: 29164656 PMCID: PMC5760282 11/23/2017       2 Citations
  • Current challenges in the management of essential thrombocythemia. (Kleman A, Singavi AK, Michaelis LC) Clin Adv Hematol Oncol 2017 Oct;15(10):773-783 PMID: 29040257 10/19/2017    
  • A Fatal Case of Erdheim-Chester Disease with Hepatic Involvement. (Balasubramanian G, Modiri A, Affi M, Hagen CE, Batdorf B, Oshima K, Michaelis L, Saeian K) ACG Case Rep J 2017;4:e95 PMID: 28798943 PMCID: PMC5541758 08/12/2017    
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 06/21/2017    
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 04/17/2017       3 Citations
  • Risk stratification in myelofibrosis: the quest for simplification. (Michaelis LC) Haematologica 2017 01;102(1):2-3 PMID: 28040786 PMCID: PMC5210226 01/04/2017       1 Citations
  • Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 01/05/2016       4 Citations
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in┬áPatients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. (Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V) Biol Blood Marrow Transplant 2016 Mar;22(3):432-40 PMID: 26493563 PMCID: PMC5030817 10/24/2015       37 Citations
  • Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014. (Michaelis LC, Erba HP) Curr Opin Hematol 2015 Mar;22(2):108-15 PMID: 25603478 01/21/2015       6 Citations
  • Mechanisms of thrombogenesis in polycythemia vera. (Kroll MH, Michaelis LC, Verstovsek S) Blood Rev 2015 Jul;29(4):215-21 PMID: 25577686 PMCID: PMC4466074 01/13/2015       14 Citations
  • Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 05/03/2014       5 Citations
  • Cutis verticis gyrata. (Walshauser MA, Birch NW, Michaelis LC) Am J Med Sci 2014 Aug;348(2):176 PMID: 23328837 01/19/2013    
  • Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 01/10/2013       54 Citations
  • Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. (Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR) Leuk Lymphoma 2013 Sep;54(9):1989-95 PMID: 23245211 12/19/2012       30 Citations
  • Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes. (Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Browning MM, Hynes DM) Pharmacotherapy 2012 Nov;32(11):988-97 PMID: 23108695 10/31/2012       3 Citations
  • Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. (Tarlov E, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM, Hynes DM) Support Care Cancer 2012 Aug;20(8):1649-57 PMID: 21935718 09/22/2011       9 Citations
  • Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. (Le H, Singh S, Shih SJ, Du N, Schnyder S, Loredo GA, Bien C, Michaelis L, Toor A, Diaz MO, Vaughan AT) Genes Chromosomes Cancer 2009 Sep;48(9):806-15 PMID: 19530238 PMCID: PMC2764312 06/17/2009       20 Citations
  • Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. (Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P) Leuk Lymphoma 2008 Nov;49(11):2141-7 PMID: 19021057 11/21/2008       54 Citations
  • Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. (Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W) Leuk Lymphoma 2008 Mar;49(3):531-7 PMID: 18297531 02/26/2008       8 Citations
  • Chimerism does not predict for outcome after alemtuzumab based conditioning. (Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K) Bone Marrow Transplant 2007 Jul;40(2):181 PMID: 17502895 05/16/2007       7 Citations
  • Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. (Michaelis LC, Ratain MJ) Clin Cancer Res 2007 Apr 15;13(8):2400-5 PMID: 17438099 04/18/2007       23 Citations
  • Measuring response in a post-RECIST world: from black and white to shades of grey. (Michaelis LC, Ratain MJ) Nat Rev Cancer 2006 05;6(5):409-14 PMID: 16633367 04/25/2006       144 Citations
  • Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? (Stadler WM, Michaelis LC, Ratain MJ) J Clin Oncol 2005 Nov 01;23(31):8124-5; author reply 8125-6 PMID: 16258115 11/01/2005       2 Citations
  • Last update: 05/06/2014
    jenkins-FCD Prod-300 626508253d14e4184314fb9f66322a03a5906796